SAR studies of diaryltriazoles against bacterial two-component regulatory systems and their antibacterial activities

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 14, 1998, Pages 1929-1934

  Zhihua, Sui ^a   Guan, Jihua ^a   Hlasta, Dennis J ^a   Macielag, Mark J ^a   Foleno, Barbara D ^a   Goldschmidt, Raul M ^a   Loeloff, Michael J ^a   Webb, Glenda C ^a   Barrett, John F ^b  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIARYLTRIAZOLE; SALICYLANILIDE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG ACTIVITY; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 0032555253     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00325-4     Document Type: Article

References (17)

1. th ACS National Meeting, Dallas, 1998. Abst. #: MEDI-39.
2. th ACS National Meeting, Las Vegas, 1997. Abst. #: MEDI-154.
3. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abst.# F-228.
4. 4. Two-Component Signal Transduction; Hoch, J. A.; Silhavy T. J., Eds.; ASM; Washington, D. C., 1995; pp 25-51.
5. 5. Parkinson, J. S. Cell 1993, 73, 857.
6. 6. Stock, J. B.; Stock, A. M.; Mottonen, J. M. Nature 1990, 344, 395.
7. 7. Hazelbauer, G. L.; Berg, H. C.; Matsumura, P. Cell 1993, 73, 15.
8. 8. Stock, J. B.; Ninfa, A. J.; Stock, A. M. Microbiol. Rev. 1989, 53, 450.
9. 9. It is worth noting that recent studies revealed that such systems exist in lower eucaryotes such as yeast and fungi, e.g. Crovello, C. S.; Furie, B. C.; Furie, B. Cell, 1995, 82, 279.
10. 10. Mustafa, A.; Hassan, A. E. A. A. J. Am. Chem. Soc. 1957, 79, 3846.
11. 11. Catarzi, D.; Cecchi, L.; Colotta, V.; Filacchioni, G.; Varano, F. J. Med. Chem. 1995, 38, 2196.
12. 50 values are the mean of two experimental determinations.
13. 13. In vitro minimum inhibitory concentration against a panel of Gram-positive bacteria: S. aureus (ATCC29213), MRSA (OC2089), E. faecalis (OC3041), E. faecium (OC3312, vancomycin resistant). Determination of susceptibility was performed following the broth microdilution method of the National Committee for Clinical Laboratory Standards.
14. 14. Terada, H.; Goto, S.; Yamamoto, K.; Takeuchi, I.; Hamada, Y.; Miyake, K. Biochimica et Biophysica Acta 1988, 936, 504.
15. 15. Topliss, J. G. J. Med. Chem. 1972, 15, 1006.
16. I, the nitrogen regulatory proteins from E. coli.
17. 17. This is a whole cell assay to monitor the function of the VanS/VanR two-component system that activates vancomycin resistance in enterococcus. High level resistance to vancomycin is determined by a group of adjacent genes organized as an operon, whose expression is under the control of the VanS/VanR two-component system. This assay measures the enzymatic activity of firefly luciferase (luc) expressed from a protein fusion to vanH, the first gene of the operon. The presence of vancomycin causes the histidine kinase to autophosphorylate and to transfer this phosphate to VanR. Phosphorylated VanR acts as a transcriptional activator of the promoter of the operon located upstream of vanH. Thus, it upregulates transcription of downstream genes, resulting in increased luciferase expression.